Dacarbazine

Form: IV Injection

Strength: 100 mg/vial, 200 mg/vial

Reference Brands: DTIC-Dome®(EU & US)

Category: Oncology Cancer Care

Dacarbazine, marketed as DTIC-Dome® (by Bristol-Myers Squibb) and available as a generic in the US and EU, is an alkylating agent used in the treatment of malignant melanoma, Hodgkin’s lymphoma, and soft tissue sarcoma. Available in 100 mg and 200 mg vials for IV injection, Dacarbazine interferes with DNA replication, preventing cancer cell division. As a trusted oncology therapy, it is sourced from GMP-compliant suppliers and is a key treatment option for oncologists targeting aggressive cancers. Dacarbazine is widely available in global US and EU markets for hospital and clinic use.